Radisa PAVLOVIC, Srdjan STEFANOVIC, Zorica LAZIC, Slobodan JANKOVIC

Factors associated with the rate of COPD exacerbations that require hospitalization

Background/aim: Exacerbations are key events in chronic obstructive pulmonary disease (COPD). Frequent exacerbations occurring during the natural course of COPD lead to deterioration of health-related quality of life and are major causes of morbidity and mortality. The aim of this study was to identify factors independently associated with frequent severe exacerbations of COPD that require hospitalization. Materials and methods: A case-control study was performed to analyze risk factors and frequency of severe exacerbations, which were defined by the GOLD guideline criteria. Stepwise multivariate regression was used to determine the significant predictors of frequent exacerbations. Results: Results revealed five independent predictors of frequent exacerbations: age, length of hospital stay, FEV1/FVC ratio, CRP level above 10 mg/L, and respiratory comorbidities. Conclusion: COPD patients should be more carefully assessed in terms of age, length of hospital stay, FEV1/FVC ratio, CRP level, and respiratory comorbidities. Patients under 65 years of age with respiratory comorbidities, longer hospital stay, lower FEV1/FVC ratio and CRP of

PDF

___

1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis. Management and Prevention of Chronic Obstructive Pulmonary Disease. Barcelona, Spain: GOLD; 2014.
2. Wan E, DeMeo D, Hersh C, Shapiro S, Rosiello R, Sama S, Fuhlbrigge A, Foreman M, Silverman E. Clinical predictors of frequent exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). Respir Med 2011; 105: 588-594.
3. Hurst J, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, Miller B, Lomas D, Agusti A, Macnee W et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128-1138.
4. Parikh R, Shah TG, Tandon R. COPD exacerbation care bundle improves standard of care, length of stay, and readmission rates. Int J Chron Obstruct Pulmon Dis 2016; 11: 577-583.
5. Montserrat-Capdevila J, Godoy P, Marsal JR, Barbé F, Galván L. Risk of exacerbation in chronic obstructive pulmonary disease: a primary care retrospective cohort study. BMC Fam Pract 2015; 16: 173.
6. Burgel PR, Nesme-Meyer P, Chanez P, Caillaud D, Carre P, Perez T, Roche N. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 2009; 135: 975-982.
7. Niewoehner DE, Lokhnygina Y, Rice K, Kuschner WG, Sharafkhaneh A, Sarosi GA, Krumpe P, Pieper K, Kesten S. Risk indexes for exacerbations and hospitalizations due to COPD. Chest 2007; 131: 20-28.
8. Hoogendoorn M, Feenstra TL, Hoogenveen RT, Al M, Molken MR. Association between lung function and exacerbation frequency in patients with COPD. Int J Chron Obstruct Pulmon Dis 2010; 5: 435-444.
9. Hurst JR. Exacerbation phenotyping in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011; 184: 625- 626.
10. Merinopoulou E, Raluy-Callado M, Ramagopalan S, MacLachlan S, Khalid JM. COPD exacerbations by disease severity in England. Int J Chron Obstruct Pulmon Dis 2016; 11: 697-709.
11. Faganello MM, Tanni SE, Sanchez FF, Pelegrino NR, Lucheta PA, Godoy I. BODE index and GOLD staging as predictors of 1-year exacerbation risk in chronic obstructive pulmonary disease. Am J Med Sci 2010; 339: 10-14.
12. Ozyilmaz E, Kokturk N, Teksut G, Tatlicioglu T. Unsuspected risk factors of frequent exacerbations requiring hospital admission in chronic obstructive pulmonary disease. Int J Clin Pract 2013; 67: 691-697.
13. Marin JM, Carrizo S, Casanova C, Martinez-Camblor P, Soriano J, Agusti AG, Celli BR. Prediction of risk of COPD exacerbations by the BODE index. Respir Med 2009; 103: 373- 378.
14. Beeh KM, Glaab T, Stowasser S, Schmidt H, Fabbri LM, Rabe KF, Vogelmeier CF. Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial. Respir Res 2013; 14: 116.
15. Kasirye Y, Simpson M, Mamillapalli CK, Epperla N, Liang H, Yale SH. Association between blood glucose level and outcomes in patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease. WMJ 2013; 112: 244- 249.
16. Brusse-Keizer M, van der Palen J, van der Valk P, Hendrix R, Kerstjens H. Clinical predictors of exacerbation frequency in chronic obstructive pulmonary disease. Clin Respir J 2011; 5: 227-234.
17. Abudagga A, Sun SX, Tan H, Solem CT. Exacerbations among chronic bronchitis patients treated with maintenance medications from a US managed care population: an administrative claims data analysis. Int J Chron Obstruct Pulmon Dis 2013; 8: 175-185.
18. Kerkhof M, Freeman D, Jones R, Chisholm A, Price DB; Respiratory Effectiveness Group. Predicting frequent COPD exacerbations using primary care data. Int J Chron Obstruct Pulmon Dis 2015; 10: 2439-2450.
19. Jurado Gamez B, Feu Collado N, Carlos Jurado Garcia J, Garcia Gil F, Munoz Gomariz E, Jimenez Murillo L, Munoz Cabrera L. Home intervention and predictor variables for rehospitalization in chronic obstructive pulmonary disease exacerbations. Arch Bronconeumol 2012; 49: 10-14.
20. McGhan R, Radcliff T, Fish R, Sutherland ER, Welsh C, Make B. Predictors of rehospitalization and death after a severe exacerbation of COPD. Chest 2007; 132: 1748-1755.
21. Liu D, Peng SH, Zhang J, Bai SH, Liu HX, Qu JM. Prediction of short term re-exacerbation in patients with acute exacerbation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2015; 10: 1265-1273.
22. Baker CL, Zou KH, Su J. Risk assessment of readmissions following an initial COPD-related hospitalization. Int J Chron Obstruct Pulmon Dis 2013; 8: 551-559.
23. Yang IA, Fong KM, Sim EH, Black PN, Lasserson TJ. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 7 CD002991.
24. Nannini LJ, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2013; 8 CD006826.
25. Bahadori K, FitzGerald JM, Levy RD, Fera T, Swiston J. Risk factors and outcomes associated with chronic obstructive pulmonary disease exacerbations requiring hospitalization. Can Respir J 2009; 16: 43-49.
26. Wang Y, Stavem K, Dahl FA, Humerfelt S, Haugen T. Factors associated with a prolonged length of stay after acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Int J Chron Obstruct Pulmon Dis 2014; 9: 99-105.
27. Roche N, Rabbat A, Zureik M, Huchon G. Chronic obstructive pulmonary disease exacerbations in emergency departments: predictors of outcome. Curr Opin Pulm Med 2010; 16: 112-117.
28. Sharif R, Parekh TM, Pierson KS, Kuo YF, Sharma G. Predictors of early readmission among patients 40 to 64 years of age hospitalized for chronic obstructive pulmonary disease. Ann Am Thorac Soc 2014; 11: 685-694.
29. Gaude GS, Rajesh BP, Chaudhury A, Hattiholi J. Outcomes associated with acute exacerbations of chronic obstructive pulmonary disorder requiring hospitalization. Lung India 2015; 32: 465-472.
30. Calverley PM, Postma DS, Anzueto AR, Make BJ, Eriksson G, Peterson S, Jenkins CR. Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations. Int J Chron Obstruct Pulmon Dis 2016; 11: 381-390.
31. Tsoumakidou M, Tzanakis N, Voulgaraki O, Mitrouska I, Chrysofakis G, Samiou M, Siafakas NM. Is there any correlation between the ATS, BTS, ERS and GOLD COPDs severity scales and the frequency of hospital admissions? Respir Med 2004; 98: 178-183.
32. Make BJ, Eriksson G, Calverley PM, Jenkins CR, Postma DS, Peterson S, Östlund O, Anzueto A. A score to predict shortterm risk of COPD exacerbations (SCOPEX). Int J Chron Obstruct Pulmon Dis 2015; 10: 201-209.
33. Almagro P, Barreiro B, Ochoa de Echaguen A, Quintana S, Rodríguez Carballeira M, Heredia JL, Garau J. Risk factors for hospital readmission in patients with chronic obstructive pulmonary disease. Respiration 2006; 73: 311-317.
34. Perez-Padilla R, Wehrmeister FC, Celli BR, Lopez-Varela MV, Montes de Oca M, Muiño A, Talamo C, Jardim JR, Valdivia G, Lisboa C et al. Reliability of FEV1/FEV6 to diagnose airflow obstruction compared with FEV1/FVC: the PLATINO longitudinal study. PLoS One 2013; 8: e67960.
35. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P et al. Standardisation of spirometry. Eur Respir J 2005: 26: 319338.
36. Jing JY, Huang TC, Cui W, Xu F, Shen HH. Should FEV1/ FEV6 replace FEV1/FVC ratio to detect airway obstruction? A metaanalysis. Chest 2009; 135: 991-998.
37. Prats E, Tejero E, Pardo P, Gavilán A, Galera R, Donado JR, Racionero MÁ, Casitas R, Zapatero A, García-Río F. Prognostic value of the six-second spirometry in patients with chronic obstructive pulmonary disease: a cohort study. PLoS One 2015; 10: e0140855.
38. Dahl M, Nordestgaard BG. Markers of early disease and prognosis in COPD. Int J Chron Obstruct Pulmon Dis 2009; 4: 157-167.
39. Jing Z, Chun C, Ning S, Hong Z, Bei H, Wan-Zhen Y. Systemic inflammatory marker CRP was better predictor of readmission for AECOPD than sputum inflammatory markers. Arch Bronconeumol 2016; 52: 138-144.
40. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 250-255.
41. Pinto-Plata VM, Müllerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS, Celli BR. C-reactive protein in patients with COPD, control smokers, and nonsmokers. Thorax 2006; 61: 23-28.
42. de Torres JP, Cordoba-Lanus E, López-Aguilar C, Muros de Fuentes M, Montejo de Garcini A, Aguirre-Jaime A, Celli BR, Casanova C. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J 2006; 27: 902-907.
43. de Torres JP, Pinto-Plata V, Casanova C, Mullerova H, Córdoba-Lanús E, Muros de Fuentes M, Aguirre-Jaime A, Celli BR. C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest 2008; 133: 1336-1343.
44. Liu SF, Wang CC, Chin CH, Chen YC, Lin MC. High value of combined serum C-reactive protein and BODE score for mortality prediction in patients with stable COPD. Arch Bronconeumol 2011; 47: 427-432.
45. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805-1812.
46. Dickens JA, Miller BE, Edwards LD, Silverman EK, Lomas DA, Tal-Singer R. COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir Res 2011; 12: 146.